Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jade Biosciences, Inc. (JBIO)
USD21.47
+0.13 (+0.61%)
US NASDAQ Healthcare Biotechnology
Address
221 Crescent Street Building 23 2453
Waltham, MA, US
Waltham, MA, US
CEO
Tom Frohlich
Website
jadebiosciences.com
IPO
2025-04-29
CIK 1798749 ISIN US0080642061
Also trades on
NASDAQ Global Market · AVTE (USD)
NASDAQ Global Market · JBIO (USD)
Description
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD21.47
+0.13 (+0.61%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
989.2K
Beta
1.43
Float Shares
24.29M
Free Float %
74.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.68% | -0.48% | +38.96% | +67.86% | +148.60% | +61.11% | +189.74% | -96.64% | -96.89% | -96.89% | -96.89% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
21.47
Low
32.00
+49.0%
Consensus
37.75
+75.8%
Median
37.00
+72.3%
High
45.00
+109.6%
DCF (Unlevered)
2.74
-87.3%
DCF (Levered)
2.80
-87.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 9 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
45.00
+109.6%
|
| Last Quarter | 2 |
42.50
+98.0%
|
| Last Year | 5 |
30.40
+41.6%
|
| All Time | 6 |
28.50
+32.7%
|
Quality scores
Altman Z-Score
19.98
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+95.2% ★ Q1'26: +77.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +1,227.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3,740.2% Q1'26: +6,876.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 EPS Ana. |
Dec 2027 7 EPS Ana. |
Dec 2028 6 EPS Ana. |
Dec 2029 4 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
107.57M
107.57M – 107.57M
|
| EBITDA |
-69.29M
|
-113.52M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-69.57M
|
-113.54M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-69.63M
est: -69.63M (+0.0%)
|
-127.41M
est: -100.14M (-27.2%)
|
-80.17M
-93.98M – -66.36M
+19.9% YoY
|
-75.51M
-94.12M – -56.89M
+5.8% YoY
|
-79.36M
-108.45M – -50.26M
-5.1% YoY
|
-82.85M
-82.85M – -82.85M
-4.4% YoY
|
-66.80M
-66.80M – -66.80M
+19.4% YoY
|
| SGA |
21.13M
|
20.42M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-85.26
est: -85.26 (+0.0%)
|
-4.06
est: -2.88 (-41.0%)
|
-2.53
-3.00 – -2.12
+12.2% YoY
|
-2.45
-3.00 – -1.81
+3.0% YoY
|
-2.43
-3.46 – -1.60
+1.0% YoY
|
-2.64
-2.64 – -2.64
-8.8% YoY
|
-2.13
-2.13 – -2.13
+19.4% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-27 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
27
Total invested
39.45M
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
27
-79 vs prev Q
New positions
5
Closed positions
83
Increased
14
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | FMR LLC | 6.89M +2.0M (+41.0%) | 106.38M +64.2M (+152.1%) | 17.42% +5.067 pp | 0.01% +0.003 pp | USD11.56 +33.5% | 3 qtrs — |
| 2 | FAIRMOUNT FUNDS MANAGEMENT LLC | 4.55M +1.3M (+41.4%) | 70.26M +42.5M (+152.8%) | 11.50% +3.368 pp | 5.35% +2.847 pp | USD11.58 +33.2% | 3 qtrs — |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 3.67M +2.6M (+245.6%) | 56.64M +47.5M (+517.9%) | 9.27% +6.590 pp | 0.58% +0.467 pp | USD13.86 +11.3% | 3 qtrs — |
| 4 | BELLEVUE GROUP AG | 3.34M +3.3M (+100.0%) | 51.55M +51.6M (+100.0%) | 8.44% +8.440 pp | 0.98% +0.977 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 5 | VR ADVISER, LLC | 3.22M +— (+0.0%) | 49.69M +21.9M (+78.8%) | 8.14% +0.000 pp | 2.45% +0.890 pp | USD9.99 +54.5% | 3 qtrs — |
| 6 | BLACKROCK, INC. | 2.87M +720.1K (+33.5%) | 44.29M +25.7M (+138.7%) | 7.25% +1.819 pp | 0.00% +0.000 pp | USD11.15 +38.4% | 3 qtrs — |
| 7 | VANGUARD GROUP INC | 2.10M +369.0K (+21.4%) | 32.34M +17.4M (+117.0%) | 5.29% +0.932 pp | 0.00% +0.000 pp | USD10.95 +40.9% | 3 qtrs — |
| 8 | BAKER BROS. ADVISORS LP | 1.64M +1.6M (+100.0%) | 25.32M +25.3M (+100.0%) | 4.15% +4.146 pp | 0.15% +0.148 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 9 | VERSANT VENTURE MANAGEMENT, LLC | 1.53M +— (+0.0%) | 23.54M +10.4M (+78.8%) | 3.85% +0.000 pp | 15.59% +9.387 pp | USD9.99 +54.5% | 3 qtrs — |
| 10 | RTW INVESTMENTS, LP | 1.45M +— (+0.0%) | 22.36M +9.9M (+78.8%) | 3.66% +0.000 pp | 0.22% +0.070 pp | USD9.99 +54.5% | 3 qtrs — |
| 11 | AVIDITY PARTNERS MANAGEMENT LP | 1.40M +273.5K (+24.3%) | 21.61M +11.9M (+122.2%) | 3.54% +0.691 pp | 6.23% +4.020 pp | USD11.05 +39.6% | 3 qtrs — |
| 12 | SAMSARA BIOCAPITAL, LLC | 968.8K +437.6K (+82.4%) | 14.95M +10.4M (+226.1%) | 2.45% +1.106 pp | 1.54% +0.944 pp | USD12.45 +23.9% | 3 qtrs — |
| 13 | DRIEHAUS CAPITAL MANAGEMENT LLC | 887.2K -368.6K (-29.4%) | 13.69M +2.9M (+26.3%) | 2.24% -0.931 pp | 0.09% +0.015 pp | USD9.99 +54.5% | 3 qtrs — |
| 14 | MARSHALL WACE, LLP | 875.3K +837.2K (+2,198.5%) | 13.51M +13.2M (+4,009.6%) | 2.21% +2.115 pp | 0.01% +0.012 pp | USD15.13 +2.0% | 2 qtrs — |
| 15 | ABRDN PLC | 867.3K +867.3K (+100.0%) | 13.38M +13.4M (+100.0%) | 2.19% +2.191 pp | 0.02% +0.021 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 841.8K +175.9K (+26.4%) | 12.99M +7.2M (+126.0%) | 2.13% +0.444 pp | 0.00% +0.000 pp | USD11.13 +38.6% | 3 qtrs — |
| 17 | GREAT POINT PARTNERS LLC | 806.3K +173.7K (+27.5%) | 12.44M +7.0M (+127.9%) | 2.04% +0.439 pp | 4.03% +1.783 pp | USD10.93 +41.2% | 3 qtrs — |
| 18 | SOLEUS CAPITAL MANAGEMENT, L.P. | 796.7K +— (+0.0%) | 12.29M +5.4M (+78.8%) | 2.01% +0.000 pp | 0.45% +0.107 pp | USD9.99 +54.5% | 3 qtrs — |
| 19 | AFFINITY ASSET ADVISORS, LLC | 715.0K +649.6K (+994.6%) | 11.03M +10.5M (+1,857.1%) | 1.81% +1.641 pp | 0.63% +0.580 pp | USD14.93 +3.3% | 3 qtrs — |
| 20 | STATE STREET CORP | 642.9K +143.6K (+28.8%) | 9.92M +5.6M (+130.2%) | 1.62% +0.363 pp | 0.00% +0.000 pp | USD10.82 +42.6% | 3 qtrs — |
| 21 | POINT72 ASSET MANAGEMENT, L.P. | 558.5K +558.5K (+100.0%) | 8.62M +8.6M (+100.0%) | 1.41% +1.411 pp | 0.01% +0.010 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 22 | ORBIMED ADVISORS LLC | 531.2K +— (+0.0%) | 8.20M +3.6M (+78.8%) | 1.34% +0.000 pp | 0.17% +0.060 pp | USD9.99 +54.5% | 3 qtrs — |
| 23 | OPALEYE MANAGEMENT INC. | 427.6K +427.6K (+100.0%) | 6.60M +6.6M (+100.0%) | 1.08% +1.080 pp | 0.87% +0.871 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 24 | LOGOS GLOBAL MANAGEMENT LP | 395.0K -230.0K (-36.8%) | 6.09M +701.1K (+13.0%) | 1.00% -0.581 pp | 0.37% -0.115 pp | USD9.99 +54.5% | 3 qtrs — |
| 25 | IKARIAN CAPITAL, LLC | 300.0K +300.0K (+100.0%) | 4.63M +4.6M (+100.0%) | 0.76% +0.758 pp | 0.36% +0.361 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 26 | CAPTION MANAGEMENT, LLC | 297.1K +297.1K (+100.0%) | 4.58M +4.6M (+100.0%) | 0.75% +0.751 pp | 0.03% +0.031 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 27 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 287.6K +287.6K (+100.0%) | 4.44M +4.4M (+100.0%) | 0.73% +0.727 pp | 0.03% +0.035 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 28 | NORTHERN TRUST CORP | 274.1K +44.5K (+19.4%) | 4.23M +2.2M (+113.5%) | 0.69% +0.113 pp | 0.00% +0.000 pp | USD10.87 +42.0% | 3 qtrs — |
| 29 | INVESCO LTD. | 199.7K +165.2K (+477.6%) | 3.08M +2.8M (+932.8%) | 0.50% +0.417 pp | 0.00% +0.000 pp | USD14.25 +8.3% | 2 qtrs — |
| 30 | AMERIPRISE FINANCIAL INC | 187.3K +187.3K (+100.0%) | 2.89M +2.9M (+100.0%) | 0.47% +0.473 pp | 0.00% +0.001 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 31 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 125.8K +32.5K (+34.9%) | 1.94M +1.1M (+141.2%) | 0.32% +0.082 pp | 0.00% +0.000 pp | USD11.40 +35.4% | 3 qtrs — |
| 32 | NUVEEN, LLC | 124.5K +81.8K (+191.3%) | 1.92M +1.6M (+420.9%) | 0.31% +0.207 pp | 0.00% +0.000 pp | USD13.56 +13.8% | 3 qtrs — |
| 33 | BANK OF NEW YORK MELLON CORP | 114.9K +32.6K (+39.5%) | 1.77M +1.1M (+149.5%) | 0.29% +0.082 pp | 0.00% +0.000 pp | USD11.48 +34.4% | 3 qtrs — |
| 34 | SOFINNOVA INVESTMENTS, INC. | 107.4K +— (+0.0%) | 1.66M +730.3K (+78.8%) | 0.27% +0.000 pp | 0.07% +0.021 pp | USD9.99 +54.5% | 3 qtrs — |
| 35 | WELLINGTON MANAGEMENT GROUP LLP | 102.6K -4.9K (-4.6%) | 1.58M +655.2K (+70.6%) | 0.26% -0.013 pp | 0.00% +0.000 pp | USD8.63 +78.8% | 2 qtrs — |
| 36 | UBS GROUP AG | 96.8K +77.0K (+388.1%) | 1.49M +1.3M (+772.6%) | 0.24% +0.194 pp | 0.00% +0.000 pp | USD14.32 +7.8% | 3 qtrs — |
| 37 | WOODLINE PARTNERS LP | 82.1K +82.1K (+100.0%) | 1.27M +1.3M (+100.0%) | 0.21% +0.207 pp | 0.00% +0.005 pp | USD15.43 +0.0% | 3 qtrs — |
| 38 | BOOTHBAY FUND MANAGEMENT, LLC | 81.1K +81.1K (+100.0%) | 1.25M +1.3M (+100.0%) | 0.21% +0.205 pp | 0.02% +0.019 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 39 | MORGAN STANLEY | 79.8K +25.5K (+47.1%) | 1.23M +762.7K (+162.9%) | 0.20% +0.065 pp | 0.00% +0.000 pp | USD11.65 +32.4% | 3 qtrs — |
| 40 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 74.4K +17.1K (+29.8%) | 1.15M +653.5K (+132.2%) | 0.19% +0.043 pp | 0.00% +0.000 pp | USD11.24 +37.3% | 3 qtrs — |
| 41 | BARCLAYS PLC | 72.2K +26.4K (+57.7%) | 1.11M +719.0K (+182.0%) | 0.18% +0.067 pp | 0.00% +0.000 pp | USD11.98 +28.8% | 3 qtrs — |
| 42 | RENAISSANCE TECHNOLOGIES LLC | 69.6K +69.6K (+100.0%) | 1.07M +1.1M (+100.0%) | 0.18% +0.176 pp | 0.00% +0.002 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 43 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 67.2K +67.2K (+100.0%) | 1.04M +1.0M (+100.0%) | 0.17% +0.170 pp | 0.00% +0.003 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 44 | GOLDMAN SACHS GROUP INC | 65.3K -97.4K (-59.8%) | 1.01M -396.0K (-28.2%) | 0.17% -0.246 pp | 0.00% +0.000 pp | USD8.63 +78.8% | 2 qtrs — |
| 45 | MILLENNIUM MANAGEMENT LLC | 62.8K +62.8K (+100.0%) | 969.1K +969.1K (+100.0%) | 0.16% +0.159 pp | 0.00% +0.000 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 46 | — | 53.2K +53.2K (+100.0%) | 820.7K +820.7K (+100.0%) | 0.13% +0.134 pp | 0.57% +0.566 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 47 | WELLS FARGO & COMPANY/MN | 51.9K +27.0K (+108.7%) | 800.7K +586.1K (+273.1%) | 0.13% +0.068 pp | 0.00% +0.000 pp | USD12.72 +21.3% | 3 qtrs — |
| 48 | RHUMBLINE ADVISERS | 50.1K +7.3K (+17.0%) | 772.3K +403.1K (+109.2%) | 0.13% +0.018 pp | 0.00% +0.000 pp | USD10.78 +43.1% | 3 qtrs — |
| 49 | ALLIANCEBERNSTEIN L.P. | 45.3K +33.3K (+276.1%) | 699.5K +595.5K (+572.4%) | 0.11% +0.084 pp | 0.00% +0.000 pp | USD13.98 +10.4% | 3 qtrs — |
| 50 | SCHRODER INVESTMENT MANAGEMENT GROUP | 39.3K +39.3K (+100.0%) | 611.0K +611.0K (+100.0%) | 0.10% +0.099 pp | 0.00% +0.001 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 51 | BANK OF AMERICA CORP /DE/ | 37.5K +22.9K (+157.3%) | 578.8K +453.0K (+360.0%) | 0.09% +0.044 pp | 0.00% +0.000 pp | USD13.31 +15.9% | 3 qtrs — |
| 52 | CITADEL ADVISORS LLC | 36.1K +36.1K (+100.0%) | 556.3K +556.3K (+100.0%) | 0.09% +0.091 pp | 0.00% +0.000 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 53 | DEUTSCHE BANK AG\ | 34.5K +4.9K (+16.4%) | 531.6K +276.2K (+108.1%) | 0.09% +0.012 pp | 0.00% +0.000 pp | USD10.60 +45.6% | 3 qtrs — |
| 54 | QUANTINNO CAPITAL MANAGEMENT LP | 29.5K +2.5K (+9.3%) | 455.1K +222.3K (+95.5%) | 0.07% +0.006 pp | 0.00% +0.000 pp | USD10.22 +51.0% | 3 qtrs — |
| 55 | XTX TOPCO LTD | 28.8K -11.5K (-28.5%) | 444.7K +96.9K (+27.9%) | 0.07% -0.029 pp | 0.01% -0.006 pp | USD9.50 +62.4% | 3 qtrs — |
| 56 | METLIFE INVESTMENT MANAGEMENT, LLC | 26.1K +12.8K (+96.2%) | 402.2K +287.6K (+250.9%) | 0.07% +0.032 pp | 0.00% +0.001 pp | USD11.96 +29.0% | 2 qtrs — |
| 57 | PRICE T ROWE ASSOCIATES INC /MD/ | 25.2K +8.9K (+54.8%) | 389.0K +248.0K (+175.9%) | 0.06% +0.023 pp | 0.00% +0.000 pp | USD11.92 +29.4% | 3 qtrs — |
| 58 | TUDOR INVESTMENT CORP ET AL | 24.2K +24.2K (+100.0%) | 373.4K +373.4K (+100.0%) | 0.06% +0.061 pp | 0.00% +0.001 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 59 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 21.5K +6.3K (+41.4%) | 332.1K +200.7K (+152.8%) | 0.05% +0.016 pp | 0.00% +0.000 pp | USD11.58 +33.2% | 3 qtrs — |
| 60 | ADAR1 CAPITAL MANAGEMENT, LLC | 21.0K +21.0K (+100.0%) | 324.0K +324.0K (+100.0%) | 0.05% +0.053 pp | 0.02% +0.024 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 61 | JPMORGAN CHASE & CO | 20.6K +7.4K (+56.1%) | 317.8K +203.9K (+179.1%) | 0.05% +0.006 pp | 0.00% +0.000 pp | USD11.94 +29.2% | 3 qtrs — |
| 62 | VIRTUS INVESTMENT ADVISERS, INC. | 17.8K +17.8K (+100.0%) | 274.0K +274.0K (+100.0%) | 0.04% +0.045 pp | 0.07% +0.075 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 63 | TWO SIGMA INVESTMENTS, LP | 16.5K -8.1K (-33.0%) | 254.5K +42.1K (+19.8%) | 0.04% -0.021 pp | 0.00% +0.000 pp | USD8.63 +78.8% | 2 qtrs — |
| 64 | DELTEC ASSET MANAGEMENT LLC | 15.8K +— (+0.0%) | 243.1K +107.1K (+78.8%) | 0.04% +0.000 pp | 0.04% +0.018 pp | USD9.99 +54.5% | 3 qtrs — |
| 65 | NEW YORK STATE COMMON RETIREMENT FUND | 14.6K +9.4K (+180.0%) | 225.6K +180.6K (+400.6%) | 0.04% +0.024 pp | 0.00% +0.000 pp | USD13.01 +18.6% | 3 qtrs — |
| 66 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 14.0K +2.9K (+26.6%) | 216.2K +120.7K (+126.3%) | 0.04% +0.007 pp | 0.00% +0.000 pp | USD11.13 +38.6% | 3 qtrs — |
| 67 | LOS ANGELES CAPITAL MANAGEMENT LLC | 21.6K +21.6K (+100.0%) | 212.5K +212.5K (+100.0%) | 0.05% +0.055 pp | 0.00% +0.001 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 68 | PERSISTENT ASSET PARTNERS LTD | 12.5K +12.5K (+100.0%) | 192.4K +192.4K (+100.0%) | 0.03% +0.032 pp | 0.09% +0.086 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 69 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 12.1K +1.7K (+16.5%) | 186.7K +97.0K (+108.2%) | 0.03% +0.004 pp | 0.00% +0.001 pp | USD10.39 +48.5% | 3 qtrs — |
| 70 | INTECH INVESTMENT MANAGEMENT LLC | 11.8K -2.3K (-16.4%) | 182.1K +60.2K (+49.4%) | 0.03% -0.006 pp | 0.00% +0.001 pp | USD9.99 +54.5% | 3 qtrs — |
| 71 | BNP PARIBAS ARBITRAGE, SNC | 9.9K -5.1K (-33.9%) | 152.3K +23.4K (+18.2%) | 0.02% -0.013 pp | 0.00% +0.000 pp | USD8.92 +73.0% | 3 qtrs — |
| 72 | RUSSELL INVESTMENTS GROUP, LTD. | 5.9K +1.5K (+34.1%) | 91.5K +53.4K (+139.8%) | 0.02% +0.004 pp | 0.00% +0.000 pp | USD11.08 +39.3% | 3 qtrs — |
| 73 | GROUP ONE TRADING, L.P. | 4.2K -1.1K (-20.4%) | 64.7K +19.3K (+42.4%) | 0.01% -0.003 pp | 0.00% +0.000 pp | USD9.99 +54.5% | 3 qtrs — |
| 74 | LEGAL & GENERAL GROUP PLC | 4.1K +1.2K (+39.8%) | 63.7K +38.2K (+150.0%) | 0.01% +0.003 pp | 0.00% +0.000 pp | USD11.54 +33.7% | 3 qtrs — |
| 75 | AMERITAS INVESTMENT PARTNERS, INC. | 3.3K +— (+0.0%) | 51.1K +22.5K (+78.8%) | 0.01% +0.000 pp | 0.00% +0.001 pp | USD9.99 +54.5% | 3 qtrs — |
| 76 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 2.9K +819.0 (+40.3%) | 44.0K +26.4K (+150.9%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD10.58 +45.8% | 2 qtrs — |
| 77 | STERLING CAPITAL MANAGEMENT LLC | 2.7K +429.0 (+19.2%) | 41.2K +21.8K (+113.1%) | 0.01% +0.001 pp | 0.00% +0.000 pp | USD10.17 +51.7% | 3 qtrs — |
| 78 | ROYAL BANK OF CANADA | 1.5K +471.0 (+46.2%) | 23.0K +14.0K (+155.6%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD11.71 +31.8% | 3 qtrs — |
| 79 | AMALGAMATED BANK | 1.5K +1.5K (+100.0%) | 22.0K +22.0K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 80 | CITIGROUP INC | 1.3K -257.0 (-16.1%) | 20.6K +6.9K (+49.9%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD9.99 +54.5% | 3 qtrs — |
| 81 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.3K -653.0 (-34.3%) | 19.3K +2.9K (+17.5%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD9.99 +54.5% | 3 qtrs — |
| 82 | STRS OHIO | 900.00 +— (+0.0%) | 13.9K +6.1K (+78.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD9.99 +54.5% | 3 qtrs — |
| 83 | NISA INVESTMENT ADVISORS, LLC | 471.00 +428.0 (+995.3%) | 7.3K +6.9K (+1,859.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD14.81 +4.2% | 2 qtrs — |
| 84 | VERSANT CAPITAL MANAGEMENT, INC | 393.00 +393.0 (+100.0%) | 6.1K +6.1K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.001 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 85 | GAMMA INVESTING LLC | 357.00 +175.0 (+96.2%) | 5.5K +3.9K (+250.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD12.44 +24.0% | 3 qtrs — |
| 86 | UBS ASSET MANAGEMENT AMERICAS INC | 210.00 +210.0 (+100.0%) | 3.2K +3.2K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 87 | DIADEMA PARTNERS LP | 1.0K +— (+0.0%) | 3.0K +204.0 (+7.4%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD8.63 +78.8% | 2 qtrs — |
| 88 | SIGNATUREFD, LLC | 128.00 +128.0 (+100.0%) | 2.0K +2.0K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD15.43 +0.0% | 1 qtrs NEW |
| 89 | ASTER CAPITAL MANAGEMENT (DIFC) LTD | 95.00 +95.0 (+100.0%) | 1.5K +1.5K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.001 pp | USD15.42 +0.1% | 1 qtrs NEW |
| 90 | PNC FINANCIAL SERVICES GROUP, INC. | 93.00 +10.0 (+12.0%) | 1.4K +719.0 (+100.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD10.57 +46.0% | 3 qtrs — |
| 91 | EVERSOURCE WEALTH ADVISORS, LLC | 89.00 +88.0 (+8,800.0%) | 1.4K +1.4K (+15,155.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD15.35 +0.5% | 3 qtrs — |
| 92 | FARTHER FINANCE ADVISORS, LLC | 77.00 +— (+0.0%) | 1.2K +523.0 (+78.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.90 +73.4% | 3 qtrs — |
| 93 | CWM, LLC | 39.00 +39.0 (+100.0%) | 1.0K +1.0K (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD15.41 +0.1% | 3 qtrs — |
| 94 | SIMPLEX TRADING, LLC | 59.00 +59.0 (+100.0%) | 910.00 +910.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD15.42 +0.1% | 1 qtrs NEW |
| 95 | ALLWORTH FINANCIAL LP | 24.00 +24.0 (+100.0%) | 371.00 +371.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD15.42 +0.1% | 1 qtrs NEW |
| 96 | LARSON FINANCIAL GROUP LLC | 23.00 +23.0 (+100.0%) | 355.00 +355.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD15.39 +0.3% | 1 qtrs NEW |
| 97 | SBI SECURITIES CO., LTD. | 14.00 -13.0 (-48.1%) | 216.00 -17.0 (-7.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.71 +77.2% | 3 qtrs — |
| 98 | ROTHSCHILD INVESTMENT LLC | 9.00 +4.0 (+80.0%) | 139.00 +96.0 (+223.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD12.22 +26.3% | 3 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 71 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.84% | 483.8K | 0.65% |
| 2 | Global X - S&P Biotech ETF CURE.AX | 0.30% | 107.2K | 0.45% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 0.30% | 32.22M | 0.35% |
| 4 | iShares Micro-Cap ETF IWC | 0.15% | 2.28M | 0.60% |
| 5 | Fidelity Fundamental Small-Mid Cap ETF FFSM | 0.15% | 2.13M | 0.43% |
| 6 | Pacer WealthShield ETF PWS | 0.06% | 14.9K | 0.60% |
| 7 | Vanguard Russell 2000 Value ETF VTWV | 0.04% | 546.0K | 0.06% |
| 8 | Avantis U.S. Small Cap Equity ETF AVSC | 0.04% | 1.25M | 0.25% |
| 9 | iShares Russell 2000 Growth ETF IWO | 0.04% | 6.28M | 0.24% |
| 10 | Direxion Daily S&P Biotech Bull 3X Shares LABU | 0.04% | 269.0K | 0.96% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
8
Sells
0
Shares acquired
1.30M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+1,301,563
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-12 | King Andrew James | Officer | A-Award | A | Common Stock | 41,250 | 0.00 | — | 386,113 | D | ↗ |
| 2026-02-12 | Frohlich Tom | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 472,500 | 14.81 | 7.00M | 472,500 | D | ↗ |
| 2026-02-12 | Dahms Bradford D. | Officer | A-Award | A | Stock Option (Right to Buy) | 226,875 | 14.81 | 3.36M | 226,875 | D | ↗ |
| 2026-02-12 | Balta Elizabeth | Officer | A-Award | A | Stock Option (Right to Buy) | 168,750 | 14.81 | 2.50M | 168,750 | D | ↗ |
| 2025-10-06 | Fairmount Funds Management LLC | Director / 10% Owner | A-Award | A | Common Stock | 1,333,126 | 9.14 | 12.18M | 1,897,677 | I | ↗ |
| 2025-07-14 | Dahms Bradford D. | Officer | A-Award | A | Stock Option (Right to Buy) | 526,000 | 9.00 | 4.73M | 526,000 | D | ↗ |
| 2025-05-16 | Frohlich Tom | Director / Officer | P-Purchase | A | Common Stock | 6,000 | 7.40 | 44.4K | 6,000 | D | ↗ |
| 2025-04-29 | Lavelle Erin | Director | A-Award | A | Stock Option (Right to Buy) | 23,017 | 10.14 | 233.4K | 23,017 | D | ↗ |
| 2025-04-29 | Klein Lawrence Otto | Director | A-Award | A | Stock Option (Right to Buy) | 23,017 | 10.14 | 233.4K | 23,017 | D | ↗ |
| 2025-04-29 | Fairmount Funds Management LLC | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 23,017 | 10.14 | 233.4K | 23,017 | D | ↗ |
| 2025-04-29 | DOBMEIER ERIC | Director | A-Award | A | Stock Option (Right to Buy) | 23,017 | 10.14 | 233.4K | 23,017 | D | ↗ |
| 2025-04-29 | CAIN CHRISTOPHER W. | Director | A-Award | A | Stock Option (Right to Buy) | 23,017 | 10.14 | 233.4K | 23,017 | D | ↗ |
| 2025-04-28 | RA CAPITAL MANAGEMENT, L.P. | 10% Owner | J-Other | A | Common Stock | 1,062,326 | 0.00 | — | 1,287,858 | I | ↗ |
| 2025-04-28 | Quick Jonathan | Officer | — | — | Stock Option (Right to Buy) | 83,801 | 1.53 | 128.2K | 0 | D | ↗ |
| 2025-04-28 | Lavelle Erin | Director | — | — | Stock Option (Right to Buy) | 88,380 | 6.03 | 532.9K | 0 | D | ↗ |
| 2025-04-28 | Kocinsky Hetal | Officer | — | — | Stock Option (Right to Buy) | 353,533 | 6.03 | 2.13M | 0 | D | ↗ |
| 2025-04-28 | Klein Lawrence Otto | Director | — | — | Stock Option (Right to Buy) | 48,720 | 6.03 | 293.8K | 0 | D | ↗ |
| 2025-04-28 | King Andrew James | Officer | — | — | Stock Option (Right to Buy) | 27,589 | 0.50 | 13.8K | 0 | D | ↗ |
| 2025-04-28 | Frohlich Tom | Director / Officer | — | — | Stock Option (Right to Buy) | 931,131 | 1.53 | 1.42M | 0 | D | ↗ |
| 2025-04-28 | Fairmount Funds Management LLC | Director / 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 2,655,817 | I | ↗ |
| 2025-04-28 | DOBMEIER ERIC | Director | — | — | Stock Option (Right to Buy) | 93,113 | 2.32 | 216.0K | 0 | D | ↗ |
| 2025-04-28 | CAIN CHRISTOPHER W. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-04-28 | Balta Elizabeth | Officer | — | — | Stock Option (Right to Buy) | 346,113 | 6.03 | 2.09M | 0 | D | ↗ |
Executive team
Top executives
Shares Outstanding
32.63M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Tom Frohlich | President, CEO & Director | 1M | male |
| Andrew James King | President of Research & Development | 765.9K | — |
| Bradford D. Dahms | CFO & Treasurer | 350.1K | male |
| Jason Wright | Senior Vice President of Chemistry, Manufacturing & Controls | — | — |
| Jonathan Quick | Senior Vice President of Finance | — | male |
| Lori Stewart | Senior Vice President of People | — | female |
| Sandy Lewis | Senior Vice President, Biometrics & Clinical Strategy | — | female |
| Amy Sullivan | Senior Vice President of Development Operations | — | female |
| Valerie Fauvelle | Senior Vice President of Regulatory & Quality | — | female |
| Edward R. Conner | Chief Medical Officer | — | — |
| Elizabeth Balta | Chief Legal Officer & Corporate Secretary | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for JBIO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
